850 related articles for article (PubMed ID: 22157079)
1. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
Kessler JD; Kahle KT; Sun T; Meerbrey KL; Schlabach MR; Schmitt EM; Skinner SO; Xu Q; Li MZ; Hartman ZC; Rao M; Yu P; Dominguez-Vidana R; Liang AC; Solimini NL; Bernardi RJ; Yu B; Hsu T; Golding I; Luo J; Osborne CK; Creighton CJ; Hilsenbeck SG; Schiff R; Shaw CA; Elledge SJ; Westbrook TF
Science; 2012 Jan; 335(6066):348-53. PubMed ID: 22157079
[TBL] [Abstract][Full Text] [Related]
2. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein A; Fallahi M; Schoeffmann S; Steidle S; Schaub FX; Rudelius M; Laitinen I; Nilsson L; Goga A; Peschel C; Nilsson JA; Cleveland JL; Keller U
Blood; 2014 Sep; 124(13):2081-90. PubMed ID: 25143484
[TBL] [Abstract][Full Text] [Related]
3. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
4. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
[TBL] [Abstract][Full Text] [Related]
5. SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways.
Yang Y; Liang Z; Xia Z; Wang X; Ma Y; Sheng Z; Gu Q; Shen G; Zhou L; Zhu H; Xu N; Liang S
Cell Commun Signal; 2019 Jul; 17(1):82. PubMed ID: 31345225
[TBL] [Abstract][Full Text] [Related]
6. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
[TBL] [Abstract][Full Text] [Related]
7. microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.
Han H; Chen Y; Cheng L; Prochownik EV; Li Y
Oncotarget; 2016 Mar; 7(13):16409-19. PubMed ID: 26918941
[TBL] [Abstract][Full Text] [Related]
8. Cancer. Taking a back door to target Myc.
Evan G
Science; 2012 Jan; 335(6066):293-4. PubMed ID: 22267799
[No Abstract] [Full Text] [Related]
9. c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2.
Li X; Liu X; Xu W; Zhou P; Gao P; Jiang S; Lobie PE; Zhu T
J Biol Chem; 2013 Jun; 288(25):18121-33. PubMed ID: 23649631
[TBL] [Abstract][Full Text] [Related]
10. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
11. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
12. p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.
Santoro A; Vlachou T; Luzi L; Melloni G; Mazzarella L; D'Elia E; Aobuli X; Pasi CE; Reavie L; Bonetti P; Punzi S; Casoli L; Sabò A; Moroni MC; Dellino GI; Amati B; Nicassio F; Lanfrancone L; Pelicci PG
Cell Rep; 2019 Jan; 26(3):624-638.e8. PubMed ID: 30650356
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
14. Targeting SUMOylation dependency in human cancer stem cells through a unique SAE2 motif revealed by chemical genomics.
Benoit YD; Mitchell RR; Wang W; Orlando L; Boyd AL; Tanasijevic B; Aslostovar L; Shapovalova Z; Doyle M; Bergin CJ; Vojnits K; Casado FL; Di Lu J; Porras DP; García-Rodriguez JL; Russell J; Zouggar A; Masibag AN; Caba C; Koteva K; Kinthada LK; Patel JS; Andres SN; Magolan J; Collins TJ; Wright GD; Bhatia M
Cell Chem Biol; 2021 Oct; 28(10):1394-1406.e10. PubMed ID: 33979648
[TBL] [Abstract][Full Text] [Related]
15. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice.
Klinakis A; Szabolcs M; Politi K; Kiaris H; Artavanis-Tsakonas S; Efstratiadis A
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9262-7. PubMed ID: 16751266
[TBL] [Abstract][Full Text] [Related]
16. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
[TBL] [Abstract][Full Text] [Related]
17. Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
Bosch A; Bertran SP; Lu Y; Garcia A; Jones AM; Dawson MI; Farias EF
Breast Cancer Res; 2012 Aug; 14(4):R121. PubMed ID: 22920668
[TBL] [Abstract][Full Text] [Related]
18. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
[TBL] [Abstract][Full Text] [Related]
19. MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities.
Rohrberg J; Van de Mark D; Amouzgar M; Lee JV; Taileb M; Corella A; Kilinc S; Williams J; Jokisch ML; Camarda R; Balakrishnan S; Shankar R; Zhou A; Chang AN; Chen B; Rugo HS; Dumont S; Goga A
Cell Rep; 2020 Mar; 30(10):3368-3382.e7. PubMed ID: 32160543
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
